Zona chez les patients atteints d'arthrite inflammatoire ou de colite ulcéreuse traités par le tofacitinib, le baricitinib ou l'Upadacitinib: Revue systématique des essais cliniques et des études en monde réel
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.
In addition, concomitant GC use was found to be a risk factor for HZ. These findings are instructive for the optimal use of JAKi and the management of HZ risk in clinical practice. They also highlighted the need for more real-world data on the efficacy and safety of the newly available HZ vaccines, and also for the comparative HZ-risk among different JAKi.
Keywords:
